NCT02297503View on ClinicalTrials.gov

Safety and Efficacy of Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster

PHASE4CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Facial Aesthetic Treatment
Interventions
DRUG

Azzalure

Glabellar lines

DEVICE

Restylane/Emervel filler

Facial tissue augmentation

DEVICE

Restylane Skinbooster

Facial skin rejuvenation

Trial Locations (3)

62000

Centre Medical Saint-Jean, Arras

06160

Mediti Center, Paris

115 42

Akademikliniken, Stockholm

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT02297503 - Safety and Efficacy of Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster | Biotech Hunter | Biotech Hunter